{
    "clinical_study": {
        "@rank": "147912", 
        "arm_group": {
            "arm_group_label": "IQP-PO-101", 
            "arm_group_type": "Experimental", 
            "description": "Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety and efficacy of IQP-PO-101 in regulating\n      the bowel movement frequency"
        }, 
        "brief_title": "IQP-PO-101 for the Regulation of Bowel Movement Frequency", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Constipation", 
            "Irregular Bowel Movement Frequency"
        ], 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A subject must have experienced 2 - 4 bowel movements per week and at least 2 of the\n             following symptoms over the preceding 3 months (self-reported):\n\n               -  Excessive straining\n\n               -  Lumpy or hard stools\n\n               -  Sensation of anorectal obstruc-tion\n\n               -  A sense of incomplete evacua-tion of bowel movements\n\n               -  A need for digital manipulation to facilitate evacuation\n\n          -  Recorded between 4 and 9 defecations in the 14-day bowel movement diary during the\n             run-in period\n\n          -  Subjects of childbearing potential must agree to use appropriate contraceptive\n             methods during run-in and treatment period\n\n          -  Commitment to avoid the use of any laxatives and/ or other medicinal products/\n             supplements that may interfere with bowel movement frequency during the run-in and\n             treatment period\n\n          -  Written informed consent.\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to the ingredients of the device\n\n          -  Any organic gastrointestinal diseases, congenital or otherwise\n\n          -  Presence of occult blood on screening\n\n          -  Constipation that may have been drug-induced\n\n          -  Use of any laxative/ products that help ease bowel movements within 7 days of the\n             screening visit\n\n          -  Constipation other than idiopathic constipation\n\n          -  Presence of other factor(s) that, in the in-vestigator's judgement, should preclude\n             subject participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809587", 
            "org_study_id": "INQ/026612"
        }, 
        "intervention": {
            "arm_group_label": "IQP-PO-101", 
            "intervention_name": "IQP-PO-101", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10369"
                }, 
                "name": "Analyze & Realize Ag"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open Label Study to Assess the Safety and Efficacy of IQP-PO-101 in Regulating Bowel Movement Frequency", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Subjects will keep a record of the number of bowel movements, if any, from 00:00 hours to 23:59 hours (midnight to midnight) daily.", 
            "measure": "Bowel movement frequency", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will keep a record of their stool form, for each bowel movement.", 
                "measure": "Bristol Stool Form Scale", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "On a 100mm visual analogue scale (VAS), subjects will rate their feeling of straining at the start/ end of defecation for each bowel movement.", 
                "measure": "Straining at the start/ end of defecation", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "On a 100mm visual analogue scale (VAS), subjects will rate their pain during defeca-tion for each bowel movement.", 
                "measure": "Pain during defecation", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "With each bowel movement, subjects will mark \"Yes\" or \"No\" to indicate whether there was a feeling of incomplete evacuation.", 
                "measure": "Feeling of incomplete evacuation", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "The subjects evaluate independently the efficacy of the investigational device (global scaled evaluation with \"very good\", \"good\", \"moderate\" and \"poor\").", 
                "measure": "Evaluation of efficacy by subjects", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The investigator evaluates independently the efficacy of the investigational device (global scaled evaluation with \"very good\", \"good\", \"moderate\" and \"poor\")", 
                "measure": "Evaluation of efficacy by investigator", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Venous blood samples are obtained at screening and the end of the treatment period (4 weeks)", 
                "measure": "Full blood count", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Venous blood samples are obtained at screening and the end of the treatment period (4 weeks) for measurements of uric acid, HbA1c and lipid profiles. An analysis will be done based on the change between the 2 periods.", 
                "measure": "Clinical chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The subjects evaluate independently the safety of the investigational device (global scaled evaluation with \"very good\", \"good\", \"moderate\" and \"poor\")", 
                "measure": "Safety evaluation by subjects", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "The investigators evaluate independently the safety of the investigational device (global scaled evaluation with \"very good\", \"good\", \"moderate\" and \"poor\")", 
                "measure": "Safety evaluation by investigators", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "InQpharm Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InQpharm Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}